Skip to main content
Clinical Trials/RBR-8zzwfn
RBR-8zzwfn
Not yet recruiting
Phase 1

Expansion of virus specific lymphocytes for cell therapy in immunosuppressed patients submitted to bone marrow transplant - : Cell therapy for CMV infection in transplanted patients

Sociedade Beneficente Israelita Brasileira - Hospital Israelita Albert Einstein0 sitesMarch 20, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Cytomegalovirus Infection
Sponsor
Sociedade Beneficente Israelita Brasileira - Hospital Israelita Albert Einstein
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 20, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Intervention

Investigators

Sponsor
Sociedade Beneficente Israelita Brasileira - Hospital Israelita Albert Einstein

Eligibility Criteria

Inclusion Criteria

  • Patients of both sexes. Patients who have undergone allogeneic bone marrow transplantation. Patients who have cytomegalovirus infection or reactivation without clinical improvement or CMV copy decline after at least 2 weeks of treatment with standard anti\-viral therapy.

Exclusion Criteria

  • Patients who have received ATG, Campath or other immunosuppressive monoclonal antibody in less than 28 days. Patients who have received infusion of donor lymphocytes in less than 28 days. Patients with other uncontrolled infections than cytomegalovirus. Patients with Grade II to IV active graft versus host disease (GVHD). Patients receiving corticosteroid therapy with equivalent or higher doses of prednisone 0\.5mg/kg.

Outcomes

Primary Outcomes

Not specified

Similar Trials